Fatigue News and Research

RSS

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient.

17 Aug 2010

Natick VNA offers checklist to help patients make informed choice of home health care provider

Home from the hospital already? As stays for hospital patients grow progressively shorter, even for procedures as serious as repairing a brain aneurysm or inserting a pacemaker, patients' need for highly skilled nursing care at home is growing. Indeed, every week, thousands of these patients are referred to home health care services.

17 Aug 2010

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

An experimental drug called olaparib has been shown to shrink tumours in women whose advanced cancers were caused by faults in their BRCA genes.

17 Aug 2010

Georgetown researcher recommends more publication on chronic sinusitis

Facial pain. Nasal congestion. Postnasal drip. Fatigue. These are hallmark signs of chronic sinusitis, a swelling of tissue in the nasal and sinus cavity. The illness strikes millions of Americans each year and is one of the top five reasons patients visit their primary care doctor. Treating sinusitis is difficult in part because it's often not known if the cause is viral or bacterial. Unfortunately little information on the subject is available to internists says a new study by a Georgetown University Medical Center (GUMC) internist.

16 Aug 2010

FDA approves ellaOne for emergency contraception

HRA Pharma announced today that the US Food and Drug Administration (FDA) granted approval for ella(R) (ulipristal acetate) as a prescription-only emergency contraceptive indicated for use within 120 hours (five days) of unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.

16 Aug 2010

Severe inflammatory response to initial UTI causes bladder damage: Research

The immune system may open the door to recurrent urinary tract infections (UTIs) by overdoing its response to an initial infection, researchers at Washington University School of Medicine in St. Louis have found.Researchers showed in mice that severe inflammatory responses to an initial UTI cause bladder damage and allow infection to persist longer. After one to two weeks of infection, the bladder wall undergoes additional changes that leave mice more vulnerable to later infection. Suppressing the immune system during initial infection decreases these vulnerabilities, they report Aug. 12 in PLoS Pathogens.

13 Aug 2010

Study finds Olaparib can reduce tumor size in ovarian cancer women

Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

13 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Secret of building muscle using light weights

Current gym dogma holds that to build muscle size you need to lift heavy weights. However, a new study conducted at McMaster University has shown that a similar degree of muscle building can be achieved by using lighter weights. The secret is to pump iron until you reach muscle fatigue.

12 Aug 2010

VA Pittsburgh selects SmartSponge System to prevent retained surgical sponge incidents

ClearCount Medical Solutions and Medline Industries, Inc. today announced that its newest customer, the VA Pittsburgh Healthcare system will help prevent retained surgical sponge incidents with the use of the SmartSponge System®. The SmartSponge System is part of ClearCount's radio-frequency identification -based platform that uniquely identifies each sponge so that they can be easily counted and detected.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

Computerized warning system alerts harmful drug orders for older hospital patients

Adverse drug events, such as dizziness or confusion occur in an estimated 40 percent of all hospital patients and can be the result of inappropriate medications being ordered. Not surprisingly, elderly individuals are particularly vulnerable to these adverse events, which not only result in longer hospitalizations, but can also pose a threat of serious complications and even death.

10 Aug 2010

BioVentrix announces First-in-Man milestone for PliCath heart failure system

BioVentrix, developer of the PliCath HF™ System for use in Epicardial Catheter-based Ventricular Reconstruction (ECVR), today announced achievement of its First-in-Man milestone, performed on a 52-year-old male heart failure patient in Krakow, Poland. The PliCath HF System is designed to treat heart failure (HF) by reducing the enlarged Left Ventricle (LV) through an anchoring system that is delivered across the cardiac chambers with the use of a catheter.

9 Aug 2010

Chicago's mold count increases to 49,789, says allergist

Chicago's mold count is 49,789 - just a few spores away from the 50,000 threshold that signals a dangerous air quality warning. Today's mold count is the highest of the season, and the highest in five years. "Headaches, sinus congestion, runny noses and fatigue will be common among Chicagoans," says Dr Joseph Leija, allergist at Loyola's Gottlieb Memorial Hospital

7 Aug 2010

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Hemispherx Biopharma, Inc. announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash expenses) for the 2nd fiscal quarter was approximately $3,676,000 or $0.03 per share compared to a loss of approximately $3,870,000 or $0.04 per share for the same period in 2009.

7 Aug 2010

Recent releases in Global Health

According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."

7 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Fatigue News and Research

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Natick VNA offers checklist to help patients make informed choice of home health care provider

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

Georgetown researcher recommends more publication on chronic sinusitis

FDA approves ellaOne for emergency contraception

Severe inflammatory response to initial UTI causes bladder damage: Research

Study finds Olaparib can reduce tumor size in ovarian cancer women

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

Secret of building muscle using light weights

VA Pittsburgh selects SmartSponge System to prevent retained surgical sponge incidents

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Computerized warning system alerts harmful drug orders for older hospital patients

BioVentrix announces First-in-Man milestone for PliCath heart failure system

Chicago's mold count increases to 49,789, says allergist

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Recent releases in Global Health

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News